We have followed, at 3, 6, 12, 24 months after the onset of therapy with LTG in add-on, 584 patients with refractory Generalized and Partial Epilepsy. 389 patients reached two years of therapy. The outcomes show that efficacy was significantly preserved in all of the various syndromes of Epilepsy.
